Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Jara-Moreno, Danielaa; c; e; 1 | Castro-Torres, Rubn D.a; c; d; f; 1 | Ettcheto, Mirena; b; c; f | Auladell, Carmed; f | Kogan, Marcelo J.e | Folch, Jaumeb; c | Verdaguer, Esterd; f | Cano, Amandac; g | Busquets, Oriola; b; c; f | Delporte, Carlae; 2 | Camins, Antonia; c; f; 2; *
Affiliations: [a] Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain | [b] Departament de Bioquímica i Biotecnologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain | [c] Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain | [d] Departament de Biologia Cellular, Fisiologia i Immunologia; Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain | [e] Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile | [f] Institut de Neurociències, Universitat Barcelona, Barcelona, Spain | [g] Departament de Farmàcia, Tecnologia Farmacèutica i Fisico-química, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain
Correspondence: [*] Correspondence to: Antoni Camins PhD, Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Avda/ Diagonal 643, E-08028 Barcelona, Spain. Tel.:+34 93 4024531; Fax:+34 934035982; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Note: [2] These authors contributed equally as senior authors.
Abstract: The most common type of dementia is Alzheimer’s disease (AD), a progressive neurodegenerative disease characterized by impairment in cognitive performance in aged individuals. Currently, there is no effective pharmacological treatment that cures the disease due to the lack of knowledge on the actual mechanisms involved in its pathogenesis. In the last decades, the amyloidogenic hypothesis has been the most studied theory trying to explain the origin of AD, yet it does not address all the concerns relating to its development. In the present study, a possible new preclinical treatment of AD was evaluated using the ethyl acetate extract (EAE) of leaves of Ugni molinae Turcz. (synonym Myrtus ugni Molina Family Myrtacea). The effects were assessed on female transgenic mice from a preclinical model of familial AD (APPswe/PS1dE9) combined with a high fat diet. This preclinical model was selected due to the already available experimental and observational data proving the relationship between obesity, gender, metabolic stress, and cognitive dysfunction; related to characteristics of sporadic AD. According to chemical analyses, EAE would contain polyphenols such as tannins, flavonoid derivatives, and phenolic acids, as well as pentacyclic triterpenoids that exhibit neuroprotective, anti-inflammatory, and antioxidant effects. In addition, the treatment evidenced its capacity to prevent deterioration of memory capacity and reduction of progression speed of AD neuropathology.
Keywords: APPswe/PS1dE9, ethyl acetate extract, high fat diet, hippocampus, neuroinflammation, Ugni molinae
DOI: 10.3233/JAD-180174
Journal: Journal of Alzheimer's Disease, vol. 66, no. 3, pp. 1175-1191, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]